The Medical Letter on Drugs and Therapeutics
Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Quartette (Teva), an extended-cycle combination oral contraceptive containing increasing doses of the estrogen ethinyl estradiol (EE) combined with the progestin levonorgestrel (LNG). The rationale is that a gradual increase in the EE dose may reduce unscheduled bleeding or spotting, a common adverse effect of extended-cycle oral contraceptives.1

CLINICAL STUDIES — In an unpublished open-label, single-arm study, 3565 women were treated with Quartette for up to 1 year (4 cycles). The pregnancy rate (Pearl Index) among women 18-35 years old, based on 70 on-treatment pregnancies, was 3.19 per 100 woman-years of use.2

An unpublished study, available only as an abstract, combined data from several clinical studies of extended-cycle combination oral contraceptives to compare the incidence of unscheduled ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive
Article code: 1420b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian